Dataset Information


L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

ABSTRACT: Through unbiased metabolomics, we identified elevations of the metabolite 2-hydroxyglutarate (2HG) in renal cell carcinoma (RCC). 2HG can inhibit 2-oxoglutaratre (2-OG)-dependent dioxygenases that mediate epigenetic events, including DNA and histone demethylation. 2HG accumulation, specifically the d enantiomer, can result from gain-of-function mutations of isocitrate dehydrogenase (IDH1, IDH2) found in several different tumors. In contrast, kidney tumors demonstrate elevations of the l enantiomer of 2HG (l-2HG). High-2HG tumors demonstrate reduced DNA levels of 5-hydroxymethylcytosine (5hmC), consistent with 2HG-mediated inhibition of ten-eleven translocation (TET) enzymes, which convert 5-methylcytosine (5mC) to 5hmC. l-2HG elevation is mediated in part by reduced expression of l-2HG dehydrogenase (L2HGDH). L2HGDH reconstitution in RCC cells lowers l-2HG and promotes 5hmC accumulation. In addition, L2HGDH expression in RCC cells reduces histone methylation and suppresses in vitro tumor phenotypes. Our report identifies l-2HG as an epigenetic modifier and putative oncometabolite in kidney cancer.Here, we report elevations of the putative oncometabolite l-2HG in the most common subtype of kidney cancer and describe a novel mechanism for the regulation of DNA 5hmC levels. Our findings provide new insight into the metabolic basis for the epigenetic landscape of renal cancer.


PROVIDER: S-EPMC4286872 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7710027 | BioStudies
2018-01-01 | S-EPMC5749504 | BioStudies
| S-EPMC4527873 | BioStudies
2016-01-01 | S-EPMC5298178 | BioStudies
| S-EPMC3271133 | BioStudies
1000-01-01 | S-EPMC3698461 | BioStudies
2014-01-01 | S-EPMC3871244 | BioStudies
2016-01-01 | S-EPMC5099755 | BioStudies
1000-01-01 | S-EPMC4385911 | BioStudies
| S-EPMC6295227 | BioStudies